Lexaria Bioscience (LEXX) Net Margin (2017 - 2026)
Lexaria Bioscience (LEXX) posted Net Margin of 7000.0% for Q1 2026, up 351.11% sequentially from 1551.72% in Q3 2025, and up 544828.0% YoY from N/an in Q1 2025.
Lexaria Bioscience (LEXX) Net Margin (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Net Margin for 10 years, with the latest figure at 7000.0% in Q1 2026.
- Quarterly Net Margin rose 544828.0% year-over-year to 7000.0% in Q1 2026, while the trailing twelve-month figure through May 2026 was 3969.07% (up 211819.0% YoY) and the FY2025 annual result came in at 1685.74%, up 43648.0% from the prior year.
- Net Margin climbed to 7000.0% in Q1 2026 per LEXX's latest filing, from 1551.72% in the prior quarter.
- Over five years, Net Margin peaked at 7000.0% in Q1 2026 and troughed at 2389.69% in Q2 2022.
- A 5-year average of 2022.09% and a median of 1847.29% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2024: Net Margin jumped 1256328 bps in 2022, then plunged 607809 bps in 2024.
- Over 5 years, Net Margin stood at 1796.64% in 2022, then surged by 144 bps to 793.24% in 2023, then soared by 85 bps to 1468.01% in 2024, then advanced by 6 bps to 1551.72% in 2025, then jumped by 351 bps to 7000.0% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 7000.0%, 1551.72%, and 2183.91% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 12.09% |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 7,000.00% |
| Aug 31, 2025 | 1,551.72% |
| May 31, 2025 | 2,183.91% |
| Feb 28, 2025 | 1,551.72% |
| Nov 30, 2024 | 1,468.01% |
| Aug 31, 2024 | 2,619.05% |
| May 31, 2024 | 2,142.86% |
| Feb 29, 2024 | 413.79% |
| Nov 30, 2023 | 793.24% |
| Aug 31, 2023 | 3,903.58% |
| May 31, 2023 | 3,088.52% |
| Feb 28, 2023 | 6,491.89% |
| Nov 30, 2022 | -1,796.64% |
| Aug 31, 2022 | -1,320.26% |
| May 31, 2022 | -2,389.69% |
| Feb 28, 2022 | 4,651.80% |
| Nov 30, 2021 | -14,359.92% |
| Aug 31, 2021 | -3,797.72% |
| May 31, 2021 | -1,253.09% |
| Feb 28, 2021 | -210.47% |